ARANESP darbepoetin alfa (rch) 100 microgram/0.5mL injection syringe with automatic needle guard Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 100 microgram/0.5ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alfa (rch) 300 microgram/0.6mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 300 microgram/0.6ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; polysorbate 80; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 15 microgram/0.38mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 15 microgram/0.38ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 39.47 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; water for injections; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 200 microgram/0.4mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 200 microgram/0.4ml injection syringe

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 500 microgram/1.0mL solution for injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 500 microgram/1.0ml solution for injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate; sodium chloride; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 80 microgram/0.4mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 80 microgram/0.4ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; sodium chloride; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 150 microgram/0.3mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 150 microgram/0.3ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 500 microgram/ml - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 20 microgram/0.5mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 20 microgram/0.5ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 40 microgram/ml - injection, solution - excipient ingredients: water for injections; polysorbate 80; sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 100 microgram/0.5mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 100 microgram/0.5ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

ARANESP darbepoetin alfa (rch) 40 microgram/0.4mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alfa (rch) 40 microgram/0.4ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.